Back to Agenda
Session 7: Global Developments & Potential Impact to Co-Development Strategies
Session Chair(s)
Lakshman Ramamurthy, PhD
Head of Global Regulatory, Precision Medicine and Digital Health
GlaxoSmithKline, United States
Megan Doyle, JD, MPH
Associate Vice President, Assistant General Counsel - Diagnostics
Eli Lilly & Company, United States
This session will discuss new developments in regulation and marketing of companion diagnostics globally, and potential impact on global development strategies. Specifically, the session will share challenges and considerations for executing global co-development programs. The session will focus primarily on regions outside of the U.S. and Europe, though discussions may include global impact of the approach in these regions.
Learning Objective : - Understand emerging developments in companion diagnostics globally.
- Explain the considerations to assess when planning global co-development strategies.
Speaker(s)
Speaker
Katherine Wang, LLM
Ropes & Gray LLP, China
Chief China Life Sciences Advisor
Speaker
Mandi Jacobson, LLM
Hogan Lovells, Australia
Partner
Speaker
Lucy Yin, MD
AstraZeneca, China
Head of Precision Medicine, China
Have an account?